Russian Watchdog Says Novo Broke Competition Law

Law360, New York (September 24, 2010, 4:34 PM EDT) -- Russian competition authorities said Friday they planned to fine Novo Nordisk A/S, the largest insulin maker in the world, for allegedly limiting competition in the pharmaceutical market.

Russia’s Federal Antimonopoly Service accused the Danish company’s subsidiary of refusing to sign contracts with individual buyers and “creating discriminatory conditions for potential partners in comparison with established ones.”

The company failed to provide economic or technological justification for the restrictions, FAS said.

The actions violated Russia’s Law "On Protection of Competition," which prohibits actions or omissions by a...
To view the full article, register now.